CPHI & PMEC India 2025 ignites pharma innovation and partnerships

For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows

Cupid reduces promoter pledged stake to 20%

This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Promotion of indigenous pharmaceutical manufacturing

PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore

Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL

With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals

Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030

Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030

Supriya Lifescience honoured for outstanding export excellence by Govt. of Maharashtra

Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium

Several technologies for hemoglobinopathies are being transferred to commercial partners